Hypothesis

Chronic activation of AMPK in senescent cells shifts the acetyl-CoA source from ACLY‑derived to ACSS2‑derived nuclear pools, thereby suppressing the SASP while enhancing lysosomal biogenesis and autophagy. This metabolic switch rewires the chromatin landscape from H3K27ac‑rich inflammatory promoters to H3K9ac‑rich repair genes, turning senescent cells into active agents of tissue homeostasis rather than passive sources of inflammation.

Mechanistic Rationale

• Senescent cells exhibit high mitochondrial citrate export via SLC25A1, feeding ACLY to produce nuclear acetyl-CoA that acetylates H3K27 at SASP loci [[https://pmc.ncbi.nlm.nih.gov/articles/PMC11643321/]].
• Concurrently, AMPK phosphorylates ACSS2 at S659, promoting its nuclear translocation under glucose stress, where it generates acetyl-CoA from acetate liberated by histone deacetylation [[https://pmc.ncbi.nlm.nih.gov/articles/PMC5521213/]][[https://pubmed.ncbi.nlm.nih.gov/28552616/]].
• We propose that AMPK activation creates a competitive advantage for ACSS2 over ACLY by (1) lowering cytosolic acetyl-CoA through increased ACLY inhibition via phosphorylation, and (2) raising nuclear acetate availability via heightened HDAC activity on SASP chromatin, which ACSS2 then recycles.
• The resulting acetyl-CoA fuels H3K9ac at TFEB‑bound lysosomal/autophagy promoters, reinforcing a clearance program that further degrades SASP mRNA and protein, establishing a negative feedback loop.

Predictions and Experimental Design

1. Pharmacological AMPK activation (e.g., AICAR or metformin) in senescent human fibroblasts will decrease nuclear ACLY levels and increase nuclear ACSS2, measurable by subcellular fractionation and western blot.
2. ChIP‑seq will show reduced H3K27ac at IL6, IL8 promoters and increased H3K9ac at LAMP1, CTSB promoters after AMPK stimulation.
3. Metabolite tracing with ^13C‑acetate will reveal elevated ^13C‑acetyl-CoA in the nucleus and decreased ^13C‑acetyl-CoA derived from glucose, confirming acetate as the dominant acetyl donor.
4. **Functionally, conditioned media from AMPK‑activated senescent cells will exhibit lower IL‑6/IL‑8 ELISA readings and higher capacity to promote macrophage phagocytosis and fibroblast migration in scratch assays.
5. **In vivo, aged mice treated with AMPK activators will show reduced SASP staining (p16^INK4a^+IL6^+) in tissues, improved gait speed, and no increase in apoptosis, indicating a shift from inflammatory to reparative senescence.

Potential Implications

If validated, this hypothesis reframes senolytics not as a blunt removal strategy but as a context‑dependent modulation of senescence phenotype. Targeting the AMPK‑ACSS2 axis could allow clinicians to retain the beneficial secretory and clearance functions of senescent cells while mitigating their detrimental inflammatory output, offering a therapeutic avenue for age‑related fibrosis, wound healing, and neurodegeneration.